This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
September 8, 2012, 10:00 am ET
Steve Smith - President, CEO
Ellis Cousens - EVP, CFOO
Drew Crum - Stifel Nicolaus
Dave Lewis - JPMorgan
Torin Eastburn - EPS Securities
Michael Corty - Morningstar
Ian Whittaker - Liberum Capital
Welcome to the John Wiley & Sons quarterly earnings call. Before introducing Steve Smith, President and Chief Executive Officer, I would like to remind you this call is being recorded and may include forward-looking statements.
You should not rely on such statements as actual results may differ materially and are subject to factors that are discussed in detail in the company's 10-K and 10-Q filings with the SEC.
The company does not undertake any obligations to update or revise forward-looking statements to reflect subsequent events or circumstances. Mr. Smith, please go ahead.
Good morning and thank you for participating in Wiley's fiscal year 2012 first quarter investor conference call. I'm with Ellis Cousens, Executive Vice President and Chief Financial Operations Officer; and Brian Campbell, Director of Investor Relations.
I'll take a few moments to write an overview of Wiley's performance in the first quarter and we will then respond to your comments and questions. Before I do so, however, I'd like to draw your attention to an 8-K statement filed on Tuesday concerning my health in which we announced that I am being treated for urologic cancer.
I have been treated surgically to remove all detectable tumor cells. I am now undergoing chemotherapy treatment to ensure that no cancer cells remain in my system. My doctor has advised that the prognosis is good for a full recovery and I expect to continue working through my treatment.